David S P Tan Selected Research

David S P Tan Research Topics

Disease

30	Neoplasms (Cancer) 01/2023 - 08/2007
13	Ovarian Neoplasms (Ovarian Cancer) 05/2023 - 10/2010
8	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2007
6	Carcinoma (Carcinomatosis) 01/2022 - 04/2009
4	Ovarian Epithelial Carcinoma 01/2021 - 04/2007
3	Endometrial Neoplasms (Endometrial Cancer) 05/2024 - 01/2022
2	Neoplasm Metastasis (Metastasis) 01/2023 - 09/2008
2	Carcinogenesis 12/2022 - 05/2014
2	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2022 - 09/2021
2	Ataxia Telangiectasia (Louis Bar Syndrome) 10/2021 - 01/2021
2	Prostatic Neoplasms (Prostate Cancer) 08/2017 - 07/2017
2	Triple Negative Breast Neoplasms 12/2013 - 09/2008
2	Ductal Carcinoma 06/2010 - 04/2009
1	Neutropenia 01/2022
1	Febrile Neutropenia 01/2022
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2021
1	Disease Progression 01/2021
1	Proteinuria 12/2018
1	Hypertension (High Blood Pressure) 12/2018
1	Diarrhea 12/2018
1	Stomach Neoplasms (Stomach Cancer) 01/2018
1	Cicatrix (Scar) 01/2018
1	Ascites 01/2013

Drug/Important Bio-Agent (IBA)

10	PlatinumIBA 05/2024 - 04/2007
6	Immune Checkpoint InhibitorsIBA 05/2024 - 09/2021
6	Paclitaxel (Taxol)FDA LinkGeneric 05/2023 - 10/2010
5	Poly(ADP-ribose) Polymerase InhibitorsIBA 08/2022 - 12/2013
5	Biomarkers (Surrogate Marker)IBA 01/2022 - 09/2008
5	Phenobarbital (Luminal)FDA Link 04/2011 - 04/2009
4	Carboplatin (JM8)FDA LinkGeneric 05/2023 - 01/2021
4	pembrolizumabIBA 12/2022 - 01/2021
4	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2011
3	lenvatinibIBA 12/2022 - 01/2022
3	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 08/2022 - 01/2015
3	DNA (Deoxyribonucleic Acid)IBA 07/2017 - 01/2007
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2023 - 04/2009
2	olaparibIBA 08/2022 - 11/2018
2	Phosphotransferases (Kinase)IBA 01/2022 - 10/2021
2	selinexorIBA 01/2022 - 01/2018
2	Trastuzumab (Herceptin)FDA Link 01/2022 - 05/2008
2	EnzymesIBA 01/2021 - 01/2015
2	Indicators and Reagents (Reagents)IBA 07/2018 - 01/2018
2	Messenger RNA (mRNA)IBA 06/2010 - 04/2009
2	AnthracyclinesIBA 09/2008 - 05/2008
1	dostarlimabIBA 12/2022
1	Angiogenesis InhibitorsIBA 08/2022
1	niraparibIBA 08/2022
1	Bevacizumab (Avastin)FDA Link 08/2022
1	tisotumab vedotinIBA 01/2022
1	cabozantinibIBA 01/2022
1	Letrozole (Femara)FDA LinkGeneric 01/2022
1	NivolumabIBA 01/2022
1	Tyrosine Kinase InhibitorsIBA 01/2022
1	ElectrolytesIBA 01/2022
1	Hormones (Hormone)IBA 01/2022
1	Immunoconjugates (Immunoconjugate)IBA 01/2022
1	Protein Kinases (Protein Kinase)IBA 10/2021
1	ParaffinIBA 09/2021
1	LipidsIBA 09/2021
1	Formaldehyde (Formol)FDA Link 09/2021
1	BAY 1895344IBA 01/2021
1	Rad51 RecombinaseIBA 01/2021
1	B7-H1 AntigenIBA 01/2021
1	Ataxia Telangiectasia Mutated ProteinsIBA 01/2021
1	ChemokinesIBA 10/2020
1	CytokinesIBA 10/2020
1	ENMD 2076IBA 12/2018
1	Irinotecan (Camptosar)FDA LinkGeneric 01/2018
1	KPT-185IBA 01/2018
1	imidazoleacetic acid (IMAC)IBA 01/2018
1	liposomal doxorubicin (Doxil)FDA Link 01/2015
1	1-dodecylpyridoxal (PLD)IBA 01/2015
1	iniparibIBA 12/2013
1	SaltsIBA 04/2013
1	Antineoplastic Agents (Antineoplastics)IBA 04/2013
1	Estrogen ReceptorsIBA 04/2009
1	ErbB Receptors (EGF Receptor)IBA 09/2008
1	Progesterone Receptors (Progesterone Receptor)IBA 09/2008
1	Tumor Biomarkers (Tumor Markers)IBA 08/2007
1	Oligonucleotide ProbesIBA 08/2007
1	Complementary DNA (cDNA)IBA 08/2007

Therapy/Procedure

14	Drug Therapy (Chemotherapy) 05/2024 - 04/2007
8	Therapeutics 01/2023 - 01/2008
5	Immunotherapy 12/2022 - 08/2017
2	Neoadjuvant Therapy 08/2022 - 01/2022
1	Radiotherapy 01/2021
1	Aftercare (After-Treatment) 01/2021